These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 470544)

  • 21. [Effect of repeated haloperidol and apomorphine administration on the development of tolerance for catalepsy and dopamine receptor hypersensitivity in mice].
    Zharkovskiĭ AM; Matvienko OA; Nurk AM
    Biull Eksp Biol Med; 1984 Oct; 98(10):444-6. PubMed ID: 6541951
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of dopamine receptor agonist treatment on haloperidol-induced supersensitivity in mice.
    Fayle P; Jackson DM; Jenkins OF; Lafferty PA
    Pharmacol Biochem Behav; 1985 Nov; 23(5):715-20. PubMed ID: 4080755
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dopamine receptor changes in response to prolonged treatment with L-dopa.
    Groppetti A; Flauto C; Parati E; Vescovi A; Rusconi L; Parenti M
    J Neural Transm Suppl; 1986; 22():33-45. PubMed ID: 2946813
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chronic neuroleptic treatment in rats produces persisting changes in GABAA and dopamine D-2, but not dopamine D-1 receptors.
    See RE; Aravagiri M; Ellison GD
    Life Sci; 1989; 44(3):229-36. PubMed ID: 2536879
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Coexistence of severe parkinsonism and tardive dyskinesia as side effects of neuroleptic therapy.
    Bitton V; Melamed E
    J Clin Psychiatry; 1984 Jan; 45(1):28-30. PubMed ID: 6141157
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of ethanol and haloperidol on dopamine receptor (D2) density.
    Fuchs V; Coper H; Rommelspacher H
    Neuropharmacology; 1987 Aug; 26(8):1231-3. PubMed ID: 3658125
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Changes in apomorphine-induced stereotypy as a result of subacute neuroleptic treatment correlates with increased D-2 receptors, but not with increases in D-1 receptors.
    Fleminger S; Rupniak NM; Hall MD; Jenner P; Marsden CD
    Biochem Pharmacol; 1983 Oct; 32(19):2921-7. PubMed ID: 6138043
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chronic domperidone fails to increase striatal spiperone binding sites despite hyperprolactinemia: comparison with chronic haloperidol.
    Morgan DG; Sinha YN; Finch CE
    Neuroendocrinology; 1984 May; 38(5):407-10. PubMed ID: 6728123
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhanced striatal 3H-spiroperidol binding induced by chronic haloperidol treatment inhibited by peptides administered during the withdrawal phase.
    Bhargava HN
    Life Sci; 1984 Feb; 34(9):873-9. PubMed ID: 6142397
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neuroleptic-induced striatal dopamine receptor supersensitivity in mice: relationship to dose and drug.
    Severson JA; Robinson HE; Simpson GM
    Psychopharmacology (Berl); 1984; 84(1):115-9. PubMed ID: 6149590
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of drug holidays in an animal model of tardive dyskinesia.
    Bannet J; Belmaker RH; Ebstein RP
    Psychopharmacology (Berl); 1980; 69(2):223-4. PubMed ID: 6779315
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dopamine receptors: effects of chronic L-dopa and bromocriptine treatment in an animal model of Parkinson's disease.
    Schneider MB; Murrin LC; Pfeiffer RF; Deupree JD
    Clin Neuropharmacol; 1984; 7(3):247-57. PubMed ID: 6435870
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Kainate lesion dissociates striatal dopamine receptor radioligand binding sites.
    Leff S; Adams L; Hyttel J; Creese I
    Eur J Pharmacol; 1981 Mar; 70(1):71-5. PubMed ID: 7215442
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chronic treatment with 1-dopa plus carbidopa in hemitransected rats: preferential effects at intact dopamine synapses leading to behavioural signs of dopamine receptor supersensitivity.
    Agnati LF; Fuxe K; Calza L; Zini I; Benefenati F; Farabegoli C; Goldstein M
    Acta Physiol Scand; 1983 May; 118(1):27-34. PubMed ID: 6137934
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of duration of haloperidol treatment on DA receptor supersensitization in aging C57BL/6J mice.
    Randall PK; Severson JA; Hurd SM; McClure WO
    Brain Res; 1985 Apr; 333(1):85-95. PubMed ID: 4039618
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alterations in dopamine receptors: effect of lesion and haloperidol treatment.
    Goldstein M; Lew JY; Asano T; Ueta K
    Commun Psychopharmacol; 1980; 4(1):21-5. PubMed ID: 6105037
    [No Abstract]   [Full Text] [Related]  

  • 37. SCH 23390 may alter dopamine-mediated motor behaviour via striatal D-1 receptors.
    Boyce S; Kelly E; Davis A; Fleminger S; Jenner P; Marsden CD
    Biochem Pharmacol; 1985 May; 34(10):1665-9. PubMed ID: 2988552
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential effects of chronic clorgyline and amfonelic acid on desensitization of striatal dopamine receptors.
    Meller E; Bohmaker K; Friedhoff AJ
    Life Sci; 1984 Oct; 35(18):1829-38. PubMed ID: 6492992
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hypophysectomy does not prevent development of striatal dopamine receptor supersensitivity induced by repeated neuroleptic treatment.
    Jenner P; Rupniak NM; Hall MD; Dyer R; Leigh N; Marsden CD
    Eur J Pharmacol; 1981 Nov; 76(1):31-6. PubMed ID: 6119220
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nigrostriatal lesions enhance striatal 3H-apomorphine and 3H-spiroperidol binding.
    Creese I; Snyder SH
    Eur J Pharmacol; 1979 Jun; 56(3):277-81. PubMed ID: 38973
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.